Table 2.

The incubation period, duration of symptoms, and time of NAT/RAT conversion to negative of IEI children following COVID-19.

		Incubation Period		Duration of symptoms		Time needed for NAT/RAT turned negative
		n	days	n	days	n	days
All		44	3.3 ± 1.9	69	8.4 ± 8.5	37	8.8 ± 5.6
Classification
	I. Combined immunodeficiencies	5	4.8 ± 1.6*	7	6.1 ± 6.5	2	9.0 ± 1.4
	II. Combined immunodeficiencies with syndromic features	3	2.3 ± 1.2	6	6.3 ± 4.2	3	7.3 ± 2.5
	III. Predominantly antibody deficiencies	15	3.1 ± 2.1	18	8.6 ± 6.8	15	10.7 ± 7.3
	IV. Diseases of immune dysregulation	5	3.6 ± 1.1	6	4.0 ± 2.6	1	5.0 ± 0.0
	V. Congenital defects of phagocytes	6	3.8 ± 2.7	7	8.3 ± 8.6	2	7.0 ± 1.4
	VI. Defects in intrinsic and innate immunity	1	5.0 ± 0.0	2	29.5 ± 29.0	1	10.0 ± 0.0
	VII. Autoinflammatory diseases	8	2.6 ± 0.7	21	8.0 ± 7.8	11	7.8 ± 4.6
	XI. Uncategorized IEIs	1	1.0 ± 0.0	2	18.0 ± 4.2	2	5.5 ± 3.5
Gender
	Male	31	3.4 ± 1.8	44	8.1 ± 7.5	26	9.4 ± 6.4
	Female	13	3.2 ± 2.2	25	8.9 ± 10.2	11	7.5 ± 2.6
Age (y)
	<2	6	2.8 ± 1.2	10	7.8 ± 6.3	4	8.0 ± 1.4
	2–5	10	3.8 ± 2.0	16	4.8 ± 3.3*	7	6.7 ± 3.5
	5–10	15	3.6 ± 1.8	20	8.4 ± 7.8	13	7.8 ± 5.0
	>10	13	2.8 ± 2.1	23	11.2 ± 11.4	13	11.2 ± 7.2
Infection sources	Household transmission	42	3.3 ± 1.9	65	8.1 ± 8.5	34	8.7 ± 5.7
	Hospital visits	2	3 ± 0.0	4	13.5 ± 7.6	3	10.7 ± 4.0
SARS-CoV-2 Vaccination
	No	29	3.6 ± 1.9	43	6.7 ± 5.8	19	7.5 ± 3.7
	Yes	15	2.8 ± 1.7	26	11.2 ± 11.3	18	10.2 ± 6.9
Pre-existing treatment
	Glucocorticoids	5	2.6 ± 0.5	15	9.7 ± 8.2	9	7.8 ± 3.4
	Immunoglobulin replacement	19	3.1 ± 2.1	21	7.0 ± 6.2	15	9.5 ± 7.4
	Biological agents	3	4.0 ± 2.6	8	7.8 ± 4.8	4	7.3 ± 4.5
	Anti-infective drugs	12	3.9 ± 2.2	16	10.1 ± 7.1	5	8.6 ± 4.4
	Immunosuppressive drugs	12	3.0 ± 1.5	21	10.0 ± 8.6	3	8.2 ± 4.3
	None	4	4.0 ± 0.8	9	11.8 ± 15.7	5	9.4 ± 3.3

*p<0.05.